{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Year+A+Pathway&page=2",
    "query": {
      "intervention": "Year A Pathway",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Year+A+Pathway&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-24T02:52:58.635Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06424522",
      "title": "A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal Cancer Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Low Anterior Resection Syndrome",
        "Rectal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Dietary Fiber",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Enema Administration",
          "type": "PROCEDURE"
        },
        {
          "name": "Loperamide Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Physical Therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "X-Ray Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2026-08-15",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-21",
      "last_synced_at": "2026-09-24T02:52:58.635Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06424522"
    },
    {
      "nct_id": "NCT04556136",
      "title": "Comparing a Novel Phototherapy Kiosk to Oral Vitamin D Supplementation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hypovitaminosis D"
      ],
      "interventions": [
        {
          "name": "Standing Phototherapy Kiosk",
          "type": "DEVICE"
        },
        {
          "name": "D3 Oral supplement",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Madigan Army Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "18 Years to 69 Years"
      },
      "enrollment_count": 106,
      "start_date": "2018-04-30",
      "completion_date": "2019-04-01",
      "has_results": true,
      "last_update_posted_date": "2024-03-13",
      "last_synced_at": "2026-09-24T02:52:58.635Z",
      "location_count": 1,
      "location_summary": "Tacoma, Washington",
      "locations": [
        {
          "city": "Tacoma",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04556136"
    },
    {
      "nct_id": "NCT02735707",
      "title": "Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Community-acquired Pneumonia, Influenza, COVID-19"
      ],
      "interventions": [
        {
          "name": "Ceftriaxone",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin or Levofloxacin",
          "type": "DRUG"
        },
        {
          "name": "Piperacillin-tazobactam",
          "type": "DRUG"
        },
        {
          "name": "Ceftaroline",
          "type": "DRUG"
        },
        {
          "name": "Amoxicillin-clavulanate",
          "type": "DRUG"
        },
        {
          "name": "Standard course macrolide",
          "type": "DRUG"
        },
        {
          "name": "Extended course macrolide",
          "type": "DRUG"
        },
        {
          "name": "No systemic corticosteroid",
          "type": "OTHER"
        },
        {
          "name": "Fixed-duration Hydrocortisone",
          "type": "DRUG"
        },
        {
          "name": "Shock-dependent hydrocortisone",
          "type": "DRUG"
        },
        {
          "name": "Fixed-duration higher dose Hydrocortisone",
          "type": "DRUG"
        },
        {
          "name": "No antiviral agent for influenza",
          "type": "OTHER"
        },
        {
          "name": "Five-days oseltamivir",
          "type": "DRUG"
        },
        {
          "name": "Ten-days oseltamivir",
          "type": "DRUG"
        },
        {
          "name": "No antiviral agent for COVID-19",
          "type": "OTHER"
        },
        {
          "name": "Lopinavir / Ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine + lopinavir/ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Ivermectin",
          "type": "DRUG"
        },
        {
          "name": "No immune modulation for COVID-19",
          "type": "OTHER"
        },
        {
          "name": "Interferon beta-1a",
          "type": "DRUG"
        },
        {
          "name": "Anakinra",
          "type": "DRUG"
        },
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        },
        {
          "name": "Sarilumab",
          "type": "DRUG"
        },
        {
          "name": "Local standard venous thromboprophylaxis",
          "type": "DRUG"
        },
        {
          "name": "Therapeutic dose anticoagulation",
          "type": "DRUG"
        },
        {
          "name": "Conventional low dose thromboprophylaxis",
          "type": "DRUG"
        },
        {
          "name": "Intermediate dose thromboprophylaxis",
          "type": "DRUG"
        },
        {
          "name": "Continuation of therapeutic dose anticoagulation",
          "type": "DRUG"
        },
        {
          "name": "No immunoglobulin",
          "type": "OTHER"
        },
        {
          "name": "Convalescent plasma",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Delayed administration of convalescent plasma",
          "type": "BIOLOGICAL"
        },
        {
          "name": "No vitamin C",
          "type": "OTHER"
        },
        {
          "name": "Vitamin C",
          "type": "DRUG"
        },
        {
          "name": "No antiplatelet",
          "type": "OTHER"
        },
        {
          "name": "Aspirin",
          "type": "DRUG"
        },
        {
          "name": "P2Y12 inhibitor",
          "type": "DRUG"
        },
        {
          "name": "No simvastatin",
          "type": "OTHER"
        },
        {
          "name": "Simvastatin",
          "type": "DRUG"
        },
        {
          "name": "Eritoran",
          "type": "DRUG"
        },
        {
          "name": "Apremilast",
          "type": "DRUG"
        },
        {
          "name": "Clinician-preferred mechanical ventilation strategy",
          "type": "PROCEDURE"
        },
        {
          "name": "Protocolised mechanical ventilation strategy",
          "type": "PROCEDURE"
        },
        {
          "name": "No renin-angiotensin system inhibitor",
          "type": "OTHER"
        },
        {
          "name": "Angiotensin converting enzyme inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Angiotensin Receptor Blockers",
          "type": "DRUG"
        },
        {
          "name": "ARB + DMX-200",
          "type": "DRUG"
        },
        {
          "name": "No cysteamine",
          "type": "OTHER"
        },
        {
          "name": "Cysteamine",
          "type": "DRUG"
        },
        {
          "name": "Fixed-duration dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Baloxavir Marboxil",
          "type": "DRUG"
        },
        {
          "name": "Five-days oseltamivir + baloxavir marboxil",
          "type": "DRUG"
        },
        {
          "name": "Ten-days oseltamivir + baloxavir marboxil",
          "type": "DRUG"
        },
        {
          "name": "No endothelial modulator",
          "type": "OTHER"
        },
        {
          "name": "Imatinib",
          "type": "DRUG"
        },
        {
          "name": "No Immune Modulator for Influenza",
          "type": "OTHER"
        },
        {
          "name": "Baricitinib",
          "type": "DRUG"
        },
        {
          "name": "Nirmatrelvir/ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Remdesivir",
          "type": "DRUG"
        },
        {
          "name": "Nirmatrelvir/ritonavir + remdesivir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "UMC Utrecht",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20000,
      "start_date": "2016-04-11",
      "completion_date": "2028-02",
      "has_results": false,
      "last_update_posted_date": "2024-07-12",
      "last_synced_at": "2026-09-24T02:52:58.635Z",
      "location_count": 11,
      "location_summary": "Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02735707"
    },
    {
      "nct_id": "NCT00295867",
      "title": "Zoledronate in Treating Bone Marrow Micrometastases in Women With Stage I, Stage II, or Stage III Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Zoledronic Acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 45,
      "start_date": "2004-11-03",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2020-05-12",
      "last_synced_at": "2026-09-24T02:52:58.635Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00295867"
    },
    {
      "nct_id": "NCT05413239",
      "title": "Healthy And Positive Pathways for Young People With Type 1 Diabetes (HAPPY T1D)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 1 Diabetes"
      ],
      "interventions": [
        {
          "name": "Psychoeducation to reduce diabetes distress and improve glycemic outcomes",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Joslin Diabetes Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "14 Years to 25 Years"
      },
      "enrollment_count": 217,
      "start_date": "2022-07-26",
      "completion_date": "2026-02-01",
      "has_results": true,
      "last_update_posted_date": "2026-03-12",
      "last_synced_at": "2026-09-24T02:52:58.635Z",
      "location_count": 2,
      "location_summary": "Palo Alto, California • Boston, Massachusetts",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05413239"
    },
    {
      "nct_id": "NCT01338857",
      "title": "Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "neurofibromatosis1 (NF1)",
        "Recurrent or Progressive Optic Pathway Gliomas (OPG)",
        "Recurrent or Progressive Low-grade Glioma"
      ],
      "interventions": [
        {
          "name": "Sorafenib (Nexavar)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2011-04",
      "completion_date": "2013-03",
      "has_results": true,
      "last_update_posted_date": "2017-02-17",
      "last_synced_at": "2026-09-24T02:52:58.635Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01338857"
    },
    {
      "nct_id": "NCT05296096",
      "title": "PRotein Optimization With eXercise to Improve MUscle Mass and Functional outcomeS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Muscle Loss",
        "Protein",
        "Mobility",
        "Pediatric ALL"
      ],
      "interventions": [
        {
          "name": "Protein dosage and rehabilitation team delivered exercise prescription",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "1 Year to 17 Years"
      },
      "enrollment_count": 18,
      "start_date": "2023-02-20",
      "completion_date": "2026-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-09-24T02:52:58.635Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Boston, Massachusetts",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05296096"
    },
    {
      "nct_id": "NCT00003765",
      "title": "O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "O6-benzylguanine",
          "type": "DRUG"
        },
        {
          "name": "carmustine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 36,
      "start_date": "1999-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-05",
      "last_synced_at": "2026-09-24T02:52:58.635Z",
      "location_count": 51,
      "location_summary": "Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 40 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003765"
    },
    {
      "nct_id": "NCT03789175",
      "title": "Nicotinamide Riboside on Mitochondrial Function in Li-Fraumeni Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cancer",
        "Skin Fibroblasts",
        "Muscle Weakness"
      ],
      "interventions": [
        {
          "name": "Nicotinamide Riboside (NR)",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 1,
      "start_date": "2019-03-25",
      "completion_date": "2019-11-01",
      "has_results": true,
      "last_update_posted_date": "2020-12-08",
      "last_synced_at": "2026-09-24T02:52:58.635Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03789175"
    },
    {
      "nct_id": "NCT06712875",
      "title": "MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Low Grade Glioma",
        "High Grade Glioma"
      ],
      "interventions": [
        {
          "name": "Trametinib and Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Dabrafenib, trametinib, nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ann & Robert H Lurie Children's Hospital of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "26 Years",
        "sex": "ALL",
        "summary": "1 Year to 26 Years"
      },
      "enrollment_count": 27,
      "start_date": "2025-04-01",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-09-24T02:52:58.635Z",
      "location_count": 3,
      "location_summary": "Washington D.C., District of Columbia • Chicago, Illinois • New York, New York",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06712875"
    }
  ]
}